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The serological hallmark in systemic lupus erythematosus is the presence of
antibodies against DNA. The studies described in this thesis center around the
induction of these antibodies, and the significance of anti-dsDNA in relation to
diagnosis and disease activity in SLE. In addition, clinical measurements of
disease activity and chronicity were evaluated in relation to the practical
clinical use of anti-dsDNA as parameter of disease activity.
Induction of antibodies against DNA
Clinical and experimental data support a role for anti-dsDNA antibodies in the
pathogenesis of SLE. The stimulus for the induction and further production of
anti-dsDNA in SLE is, however, unknown. Various experimental data suggest
a role for the microflora in auto-immune diseases. With respect to SLE,
invasion of foreign bacteria from the intestines may result in polyclonal
activation of the immune system and/or induce anti-dsDNA antibodies by a
process of molecular mimicry. Indeed, bacterial DNA has been shown to be
immunogenic. Normally, invasion of foreign bacteria is prevented by various
host factors amongst which the colonization resistance is of primary
importance. The colonization resistance is the defence capacity of the
indigenous microflora against colonization by foreign bacteria. We found that
SLE patients, both during inactive and active stages of the disease, tended to
have a colonization resistance lower than healthy individuals (Chapter 2). A
lower colonization resistance could imply that in SLE patients more different
bacteria may translocate across the gut wall. Some of these bacteria may serve
as antigen for the production of anti-bacterial antibodies cross-reacting with
autologous DNA. In Chnpter 3, we found that in both inactive and active SLE
patients IgM titres against their own faecal microflora were lower in
comparison to healthy individuals. This was interpreted as a failing
against bacterial antigens in SLE. IgG-class antibacterial antibodies
increased in inactive patients and decreased in active patients. The former i
consistent with a higher degree of bacterial translocation. We suggested
the observed decrease of lgG-class antibacterial antibodies during
disease might result from usage of these antibodies in formed i
complexes. A similar phenomenon, i.e. a sharp decrease in anti-dsDNA
been shown during relapses of SLE. To analyze the specificity of the i
antibodies, with respect to their reactivity to bacterial antigens from the
microflora, dissoci:
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microflora, dissociation of immune complexes from sera from patients with
active disease has to be performed vet.
Measurement of antïdsDNA, diagnostic tool and targeÍ for teatment in SLE
For the determination of anti-dsDNA different assay methods are available,
which differ in their sensitivity and specificity with respect ro rhe diagnosis of
SLE. In Chapter 4 we determined the diagnostic value of three different
assays (Farr, ELISA and Crithidia luciliae immunofluorescence t st) and
concluded that the Farr assay, using t25I recombinant DNA as substrate,
appeared to be the test with the highest specificity and sensitivity for SLE. In
this cross-sectional study special attention was paid to the diagnostic
significance of IgM-class anti-dsDNA. In SLE, but also in other auto-immune
diseases IgM-class anti-dsDNA could be detected. We found that all SLE sera
positive for lgM-class anti-dsDNA but negative for IgG-class anti-dsDNA as
detected by ELISA, were positive by the Farr assay. In contrast, most of the
sera positive for IgM-class anti-dsDNA Íiom patients with diseases other than
SLE were negative when tested by the Farr assay.
In Chapter 5, we investigated in a longitudinal study, the predictive
value of rises in IgM-class anti-dspNA by ELISA for ensuing relapses in
SLE, in comparison to rises in IgG-class anti-dsDNA by ELISA and rises in
anti-dsDNA as detected by Farr assay. We found that the cumulative risk for
relapses did not differ significantly between patients with rises in lgM-class
anti-dsDNA and those without a rise in IgM-class anti-dsDNA. Moreover, no
specific clinical manifestations of SLE were associated with rises in IgM-class
anti-dsDNA antibodies. In contrast, patients with rises in IgG-class anti-
dsDNA measured by ELISA and anti-dsDNA by Farr assay had a significantly
higher cumulative risk for relapses than patients without those rises.
Clinical measures of disease activity in systemic lupus erythematosus
In order to assess prognosis and to evaluate the effect of diÍferent treatment
strategies in SLE patients it is evident that both clinical disease and damage
measures are required. Three indices, the Systemic Lupus Activity Measure
(SLAM), the SLE Disease Activity Index (SLEDAI) and the Brirish Isles
Lupus Assessment Group (BILAG), are considered to be reliable and validated
measures of clinical disease activity in patients with SLE. In Chapter 6 we
compared these indices in their sensitivity to measure change over time. We
t25
Chapter 9
concluded that SLAM appeared to be most sensitive to measure change in
disease activity over time. BILAG was slightly less sensitive compared to
SLAM, but has the advantage of measuring disease activity per organ system.
SLEDAI appeared to be the less sensitive. In addition, we demonstrated that
changes in disease activity measured by SLAM and BILAG correlated
significantly with changes in levels of anti-dsDNA. The overall use of one
index would greatly enhance the possibility of compàring clinical studies from
various centers.
Measurement of anti-dsDNA as guide for treatment in SLE
The observed risk for relapses after rises in IgG-class anti-dsDNA by ELISA
and rises in anti-dsDNA determined by Farr assay (Chapter 5,) were in
accordance with a previous finding, showing that rises in lgG-class anti-
dsDNA by ELISA preceded a clinical relapse in 74% of the cases, and rises
detected by Farr assay in 89% of the cases. Rises in anti-dsDNA could
already be detected 8 to 10 weeks before the relapse occurred. Accordingly,
we performed a prospective randomized controlled trial aimed at the
prevention of clinical relapses in SLE patients by treatment based on rises in
levels of anti-dsDNA (Chapter 7). When a rise in anti-dsDNA was detected,
patients were randomly assigned either to conventional treatment or to early
treatment with 30 mg prednisone in addition to current therapy. In the group
of patients assigned to conventional treatment (n:24) 20 out of the 24 patients
developed a relapse, whereas only two relapses occurred in the early treatment
group (n:22). The mean daily doses of prednisone differed significantly
between the two treatment arms, although the cumulative doses of prednisone
did not differ the groups. Thus, changes in anti-dsDNA antibodies can be used
as target for treatment. Further studies should reveal whether the dose of
prednisone required for prevention of relapses can be reduced or whether
specific therapy aimed at the eradication of anti-dsDNA producing B cells is
possible.
Measuring of damnge in systemic lupus erythematosus
In SLE patients, it is important to be able to evaluate the effect of treatment
not only in terms of reducing disease activity, but also in terms of reducing
accumulated damage over time. Recently, an index for damage in SLE
patients, the SLICC/ACR (Systemic Lupus International Collaborative Clinics/
American College
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American College of Rheumatology) damage score has been developed.
Damage in SLE may result from previous disease activity leading to organ
failure, from medication, or from intercurrent illness, such as surgery or
cancer. In Chapter 8 we evaluated the usefulness of this damage score in SLE.
This damage index appeared to be sensitive to measure change over time. The
damage index reflects cumulative disease activity, especially of kidneys and
haematologic systems, as well as cumulative doses of prednisone. We used
this damage score in the clinical trial described in (Chapter 7) and found that
in both treatment arms the damage score increased significantly, although the
change in damage score was not significantly different between both treatment
groups. We concluded that the SLICC/ACR damage score appeared to be a
useful outcome parameter in SLE. However, further evaluation in long-term
prospective studies is needed.
Concluding remnrks
With respect to the questions posed in Chapter 1 we conclude:
1. Colonization resistance seems decreased in SLE and higher levels of
antibodies against autologous bacterial flora are presented in SLE. This is
compatible with a role for autologous bacterial flora in the induction
and/or activation of anti-dsDNA production in SLE (Chapter 2 and 3).
2. The r2sl Farr assay has the highest sensitivity and specificity for detecting
antibodies against double-stranded DNA as diagnostic tool for SLE. Serial
quantitation of anti-dsDNA levels by this assay can be used. Rises of IgM-
class anti-DNA, in contrast to rises in IgG-class anti-dsDNA, are not a
sensitive tool for predicting relapses in SLE (Chapter 4 and 5).
3. SLAM and BILAG appeared to be sensitive disease activity measures. The
SLICC / ACR damage score is auseful measure of damage (Chapter 6-8).
4. Treatment based on rises in anti-dsDNA prevents relapses in most cases in
SLE (Chapter 7).
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